IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 23, Issue 10 Ser. 10 (October. 2024), PP 18-24
www.iosrjournals.org

Antibiotic Resistance And The Future Of Infection Control

Juturu Revathi Devi*, Mantri Satyavathi, Gunturu Varsha, Syed Reshma, Shaik Sharmila, Panchumarthy Ravisankar
Vignan Pharmacy College, Vadlamudi, Guntur, A.P, India.

***Abstract**:*
This review article focuses on the essential topic of antibiotic resistance, a growing global health threat that calls into question the efficacy of previously effective therapies. It starts by recognizing the enormous influence that antibiotics, which were discovered in the 20th century, have had on medicine. Despite their effectiveness in treating infections, these medications' overuse and abuse have had unforeseen repercussions. Pathogens have evolved a number of defense mechanisms against antibiotics as their usage in human healthcare, agriculture, and animal husbandry has increased. This resistance extends throughout communities and the environment in addition to occurring in clinical settings. The paper emphasizes how environmental variables, agricultural runoff, and other microbes can all contribute to the acquisition of resistance genes. It highlights how gene transfer contributes to the rapid proliferation of resistant strains. The worldwide nature of travel and trade adds to the complexity of this problem by making it easier for resistant germs to spread across national boundaries. Many antibiotics could become ineffective as a result of this resistance crisis, which would raise healthcare expenses, lengthen hospital stays, and raise mortality rates. The essay emphasizes the necessity of a multipronged strategy, including improved antibiotic stewardship, surveillance initiatives, and public education, to counter this threat. It urges cooperation between researchers, legislators, and healthcare professionals in order to create novel remedies and encourage the prudent use of antibiotics. In order to protect public health for future generations, the review intends to increase awareness and motivate action against the spread of antibiotic resistance by addressing these interrelated issues.

Keywords: *Antibiotic resistance, Transmission of illness,* β-lactamase enzymes, *resistant strains, multipronged strategy.*

Date of Submission: 13-10-2024 Date of Acceptance: 23-10-2024

I. Introduction

Drugs called antibiotics are used to both treat and prevent bacterial illnesses. When bacteria adapt to the use of antibiotics, antibiotic resistance develops. Both humans and animals can contract illnesses from these germs, and treating those infections is more difficult than treating infections from non-resistant bacteria. Antibiotic resistance raises the expense of healthcare, lengthens hospital stays, and increases death rates. The way antibiotics are prescribed and used in the world must alter immediately. Antibiotic resistance will continue to pose a serious concern even in the absence of new medication developments and behavioral changes. Changes in behavior must also involve steps to stop the transmission of illnesses, such as being vaccinated, washing your hands, having safer sexual relations, and maintaining proper food hygiene. [1]

Mechanism of action:

It has involved investigations of the genetics and biochemistry of many different facets of bacterial cell function. Genes generating β-lactamase enzymes are likely the most widely distributed in the world; accidental mutations in these genes have produced modified catalysts with progressively wider resistance spectrum Gram-positive infections are commonly treated with macrolide antibiotics, which were developed to address the issue of methicillin resistance. Examples of these antibiotics are erythromycin and its derivatives. The way that the macrolides and related antibiotics work is by binding to various locations inside the 50S ribosomal subunit's peptide escape tunnel. Resistance may arise from changes made to the tunnel's RNA or protein constituents. Recently, (88) a unique rRNA alteration was reported that confers resistance to all antibiotics acting at this point on the ribosome. This modification is on the rise.[2]

TABLE-1: Mode of action and resistance mechanisms of commonly used antibiotics [1]

Antibiotic class	Example(s)	Target	Mode(s) of resistance
β-Lactams	Penicillin's(ampicillin), cephalosporins(cephamycin) (meropenem),monobactams (aztreonam)	Peptidoglycan biosynthesis	Hydrolysis, efflux, altered target
Aminoglycosides	Gentamicin,streptomycin, spectinomycin	Translation	Phosphorylation ,acetylation, nucleotidylation, efflux, altered target.
Glycopeptides	Vancomycin, teicoplanin	Peptidoglycan biosynthesis	Reprogramming peptidoglycan biosynthesis.
Tetracyclines	Minocycline, tigecycline	Translation	Monooxygenation, efflux, altered target.
Macrolides	Erythromycin, azithromycin	Translation	Hydrolysis, glycosylation, phosphorylation, efflux, altered target.
Lincosamides	Clindamycin	Translation	Nucleotidylation, efflux, altered target.
Streptogramins	Synercid	Translation	C-O lyase (type B streptogramins), acetylation (type A streptogramins) efflux, altered target.
Oxazolidinones	Linezolid	Translation	Efflux altered target.
Phenicol's	Chloramphenicol	Translation	Acetylation, efflux, altered target.
Quinolones	Ciprofloxacin	DNA replication	Acetylation, efflux, altered target.
Pyrimidines	Trimethoprim	C_1 metabolism	Efflux, altered target
Sulfonamides	Sulfamethoxazole	C_1 metabolism	Efflux, altered target
Rifamycin	Rifampin	Transcription	ADP-ribosylation, efflux, altered target.

Area Where Resistance Is Higher and Where Antibiotics Are Used More:

Most of these infections are related to catheter use and surgical operations, and they happen in hospitals and other healthcare facilities. An antibiotic called carbapenem is used to treat some Enterobacteriaceae infections that are resistant to other antibiotics. But the bacteria may also develop carbapenem resistance. [3,4,5]

Response to resistance:

Antibiotic usage is the primary cause of antibiotic resistance. Antibiotic use kills some germs; however resistant bacteria can live and even grow. Antibiotic usage increases the prevalence of resistant bacteria. Bacteria naturally develop resistance to antibiotics. But what we do can strengthen the resistance against growth and dissemination. This is possible:

1. When medical practitioners over prescribing antibiotics to humans and animals
2. When patients fail to take medicines as prescribed
3. Because of inadequate hand washing practices and a lack of infection prevention and control measures.
4. As a result of humans traveling the globe and transferring microorganisms that are resistant.
5. Activate specific internal resistance mechanisms.
6. Adapt to fend against an antibiotic.
7. Acquire genes for resistance from other bacteria.[6]

Which Entity Produce Higher Antibiotic Resistance:

1. Staphylococcus aureus resistant to methicillin (MRSA)
2. Streptococcus pneumoniae resistant to drugs
3. Enterococcus vancomycin resistant (VRE)
4. Pseudomonas aeruginosa resistant to many drugs
5. Diffuse Clostridium difficile
6. Enterobacteriaceae resistant to carbapenems (CRE)
7. Mycobacterium tuberculosis with multiple drug resistance (MDR-TB)
8. Acinetobacter resistant to carbapenem
9. Resistant to drugs Gonorrhea gonorrhoeae
10. Candida auris resistant to drugs. [7]

Which Drug Develops a Higher Resistance:

When cefoxitin, ciprofloxacin, or erythromycin inhibits E. coli and Enterococcus, they typically exhibit resistance to one or more antibiotics, and occasionally to multiple antibiotic classes such as rifamycin, beta-lactams, macrolides, quinolones, sulfonamides, and tetracyclines.

In The Age of Antibiotic Resistance: Surgical Antibiotic Prophylaxis:

Notes: Table 1 is not exhaustive of all possible organisms and bacterial resistance associated with surgical site infection; resistance may vary across different institutions; always follow site-specific resistance patterns and protocols where available. Table 2 lists examples of bacteria and antibiotic resistance encountered in surgical site infection by surgical procedure. Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. are common Enterobacter seen in surgical site infections.

Abbreviations: VRE stands for vancomycin-resistant Enterococcus; CRE for carbapenem-resistant Enterobacter; FR-GNB for fluoroquinolone-resistant Gram-negative bacteria; MRSA for methicillin-resistant Staphylococcus aureus; ESBL producers for extended-spectrum β-lactamase-producing bacteria.

Examples of Bacteria Implicated in Surgical Site Infection Categorized by Surgical Procedure is tabulated in table 2.

Table-2

Procedure	Example of Bacteria Associated with Surgical Site Infection.	Examples of Possible Antibiotic Resistance Encountered
Gastrointestinal surgery	Enterococcus spp., Gram-positive cocci (Streptococcus spp.), Enterobacter, anaerobes	VRE, ESBL producers, CRE
Gynecological surgery	Staphylococcus aureus, Group B Streptococcus, Enterococcus spp., Enterobacter	MRSA, VRE, ESBL producers
Head, oral and neck surgery	Staphylococcus aureus, Enterobacter, Pseudomonas aeruginosa, anaerobes	MRSA, ESBL producers
Orthopedic surgery	Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus spp., Enterobacter, Pseudomonas aeruginosa, anaerobes	MRSA, ESBL producers
Urological surgery	Gram-negative bacilli, Enterococcus spp., Enterobacter	VRE, ESBL producers, FR-GNB, CRE
Vascular surgery	Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus spp., Enterobacter, Pseudomonas aeruginosa	MRSA, VRE, ESBL producers

Surgical antibiotic prophylaxis's common agents and potential substitutes to consider:

Table 3 lists popular surgical antibiotic prophylactic drugs along with examples of potential substitutes based on their underlying spectrum of activity that may be considered for resistant microorganisms. Definitions: +++ denotes high antibiotic activity, ++ denotes moderate antibiotic activity, + denotes low antibiotic activity, and - denotes minimal to no antibiotic activity. There is little data to compare the effectiveness of surgical antibiotic prophylaxis with other agents for bacteria that are resistant to antibiotics; unnecessary use may amplify resistance; careful selection is advised in conjunction with guidelines on infectious diseases and medical microbiology**.**[7]

Table-3

Antibiotic	Antibiotic Class	Bacterial Coverage	Role in Surgical Antibiotic Prophylaxis
Cefazolin	β-lactam	Gram-positive ++ Gram-negative + Anaerobes +	Gram-positive and limited Gram-negative cover. Common for many surgical procedures.
Clindamycin	Lincosamide	Gram-positive ++ Gram-negative Anaerobes ++	Gram-positive cover, typically reserved for patients with immediate hypersensitivity to β-lactam antibiotics.
Gentamicin	Aminoglycoside	Gram-positive - Gram-negative +++ Anaerobes -	Gram-negative cover, commonly used in urological and gastrointestinal surgery.

Vancomycin	Glycopeptide	Gram-positive +++ Gram-negative -	Gram-positive cover, typically reserved for patients with immediate hypersensitivity to β-lactam antibiotics or patients with MRSA.
Meropenem/Ertapenem	Carbapenem	Gram-positive ++ Gram-negative +++ Anaerobes ++	Consider ESBL producers and sensitivity to carbapenems. Avoid in suspected immediate hypersensitivity to β-lactams.
Fosfomycin	Oxazolidinone	Gram-positive + Gram-negative ++ Anaerobes -	Consider for transrectal prostate biopsy in patients complicated with or suspected fluoroquinolone resistant bacteria (mostly *E. coli*)
Daptomycin	Cyclic lipopeptide	Gram-positive +++ Gram-negative - Anaerobes +	Consider VRE. Could also be considered for MRSA where vancomycin or teicoplanin contraindicated.
Linezolid	Oxazolidinone	Gram-positive +++ Gram-negative - Anaerobes +	Consider VRE. Could also be considered for MRSA where vancomycin or teicoplanin contraindicated.
Tigecycline	Glycylcycline	Gram-positive ++ Gram-negative ++ Anaerobes ++	Consider the cover of VRE and MRSA where vancomycin, daptomycin and/or linezolid are contraindicated. Avoid in suspected hypersensitivity to tetracyclines

II. Methods To Get Across Antibiotic Resistance

Getting Rid of Antibiotic Resistance in Microorganisms-

- **β-lactamase inhibitors**: Given the widespread usage of β-lactam antibiotics, it is crucial to maintain the capabilities of these substances. The basis for resistance to β-lactam antibiotics is the β-lactamases' hydrolysis of the lactam ring. When these enzymes are inhibited in addition to antibiotics, the antibacterial action of β-lactams is maintained. The review by Egorov et al. presents the structures, methods of action, and potential applications of several generation inhibitors. [8]
- **Peptidoglycan-recognizing proteins**: A wide range of other antibacterial preparations target cell membrane-related cell structures. Peptidoglycan-recognizing proteins, as detailed in Bobrovsky et al.'s review, are among these preparations. These proteins are the components of innate immunity because they can bind bacterial peptidoglycan. The authors propose a novel method for modifying the genome of human cells that may enhance the expression of genes producing proteins that recognize peptidoglycans. [9]
- **Lanthipeptides are peptide antibiotics:** A class of antibiotics known as lanthipeptides was described by Gabino et al. Except for vancomycin, peptide antibiotics have not been widely used up to this point because of their poor specificity, volatility, and production issues. The authors propose a novel method for producing a broad range of genetically modified primary structural peptide antibiotics and using microfluidic technology to evaluate the resulting antimicrobial peptides for biological activity.[10]
- **Antibiotics and methylation:** Antibiotics frequently target the ribosomal functional centers in bacteria. One method of resistance to macrolides and other antibiotics is methylation of nucleotide residues by methyltransferases. In the review of Dontsova et al. methylation processes in various ribosome sites that confer resistance to various antibiotic groups are described. The authors also covered the genetic processes that lead to methyltransferase production and how antibiotic resistance has evolved because of these processes. [11]
- **Bacteriophages:** An antiquated method for combating microorganisms resistant to many drugs. Bacteriophages, being viruses of bacteria, have genetic mechanisms that enable them to overcome resistance. Bacteriophages are selective against specific infectious agents, unlike antibiotics, which typically show broad-spectrum activity. This characteristic influences the large-scale manufacturing and use of bacteriophages. Through genetic engineering techniques, bacteriophages' traits can be modified, increasing their potential applications. This subject is covered in the polemical review on the application of bacteriophages in medicine by Vlasov et al. [12].

Antibacterial medicines can now be obtained from marine microbes. Several structurally diverse antimicrobial metabolites, many lacking an equivalent, have been identified from marine bacterial extracts. The paper by Stonick et al. reviews the research on these antibiotics. Numerous stages of pre-clinical and clinical trials are being conducted for these products. [13]

- **New generation antibiotics**: Shemya kin et al. present a variety of strategies for addressing the issue of bacterial resistance, including those based on the application of CRISPR-Cas systems and small non-coding RNAs (sRNA), which are crucial for controlling the genetic processes in bacteria. These techniques are still at the experimental stage of development, but from a scientific perspective, they are highly significant. The writers focus specifically on proteins and cellular process inhibitors, including biofilms, virulence factors, efflux pumps, transmembrane transport, β-lactamases, and cell-cell communication pathways. While many of these inhibitors are still being studied scientifically, some have already found practical use in medicine. [14]

The fact that many inhibitors are peptides, however, means that there are new avenues for the development of antimicrobial drugs. Stimulating innate immunity is another area in which peptides are applied, and this could also serve as a foundation for the development of antimicrobial preparations. Recombinant endolysins, which break down bacterial cell walls and biofilms, are currently being tested in clinical trials. Another urgent problem is the development of biocompatible surfaces for transplanted organs. The review covers various methods for synthesizing nanomaterials with antibacterial properties.[15]

The current abuse of antibiotics has even increased the effectiveness of these developing defenses, causing bacterial strains that are resistant to the relevant clinical medications to arise. In addition to these resistance mechanisms, bacteria can form biofilms that are resistant to extremely high concentrations of various antimicrobials and stick to surfaces. According to Saini and Saini (2011), biofilms are composed of a sorted and synchronized group of sessile cells embedded in an extracellular polymeric matrix that they have manufactured on their own.[16,17]

They can develop on foreign devices that have been put into the body, such as catheters and orthopedic prosthesis, as well as in any area of the body where the host's defenses are weak, such as chronic wounds with reduced blood flow (Bjarnsholt 2013).[18]

According to Lebeaux and Ghigo (2014), biofilm-related illnesses are challenging to cure and usually need extended medical care to reduce the burden of illness. The development of contemporary medicine and the widespread use of medical devices are factors contributing to the rising occurrence of these infections (Saini and Saini 2011; Shorr and Lodise 2006).[19]

III. Future perspectives

A serious threat to world health is the emergence of antibiotic resistance, which calls for creative approaches to infection prevention. Several important viewpoints become apparent as we gaze to the future:

Enhanced Surveillance: Monitoring antibiotic-resistant illnesses requires better worldwide surveillance networks. Antibiotic stewardship initiatives and public health interventions can be guided by this data.

Antibiotic Stewardship Programs: It is essential to highlight appropriate prescribing practices among medical professionals. Reducing needless antibiotic usage and educating patients and healthcare professionals about the dangers of overuse should be the goals of these initiatives. Research and development of new antibiotics and other treatments should be a top priority for the pharmaceutical business. This include investigating novel antibiotic classes and repurposing already-approved medications.

Phage Therapy and Alternatives: Bacteriophage therapy, which uses viruses that selectively target bacteria, offers promise as an alternative to standard antibiotics. Continued research in this area could give new therapy options.

Vaccination Strategies: The prevalence of diseases that need antibiotic treatment can be considerably decreased by creating vaccinations against bacterial pathogens. Improved immunization campaigns may stop illnesses before they start.

Public Awareness Campaigns: It's critical to increase public knowledge of antibiotic resistance and the appropriate use of antibiotics. Patients can be empowered to participate in healthcare decision-making through education programs.

One Health Method: A holistic approach to combating antibiotic resistance is fostered by integrating environmental, animal, and human health measures. This all-encompassing strategy can assist in addressing the root of the problem.

Regulatory Policies: Lawmakers must enact and uphold laws that restrict the use of antibiotics in farming and encourage ethical behavior in medical facilities.

Infection Control Procedures: Preventing the spread of resistant infections can be achieved by bolstering infection control protocols in both community and hospital settings. This covers isolation techniques, sterilizing procedures, and hand hygiene.

International Cooperation: To effectively combat antibiotic resistance, international cooperation is essential. Cross-border exchange of information, resources, and best practices will strengthen teamwork. By implementing these tactics, we may better equip ourselves to handle the problems caused by antibiotic resistance, which will ultimately lead to more efficient infection control and protect public health for coming generations.

IV. Discussion

Introduction:

Antibiotic resistance is undermining the effectiveness of antibiotics, which are crucial in treating bacterial illnesses. This phenomenon occurs when bacteria change in reaction to antibiotic exposure, resulting in more challenging-to-treat illnesses. Antibiotic resistance has serious repercussions, including greater death rates, longer hospital admissions, and higher healthcare expenses. As a result, prescription practices and usage patterns for antibiotics must be changed right once**.**

Mechanism of action:

Genetic changes that alter the activities of bacterial cells are frequently connected to antibiotic resistance mechanisms. For example, β-lactam antibiotics can be hydrolysed by the development of β-lactamase enzymes, which makes them ineffective. The 50S ribosomal subunit is the target of macrolides like erythromycin, however resistance may also arise from changes in ribosomal RNA or protein constituents. This demonstrates how microorganisms can adapt to pharmacological interventions**.**

Areas where resistance is higher and where antibiotics are used more:

Antibiotic-resistant infections, which are frequently linked to catheter use and surgical operations, are especially common in hospital settings. Although carbapenems work well against some resistant strains, they are not impervious to resistance. To slow the spread of resistant pathogens, these environments require strict infection control methods.

Response to resistance:

The abuse of antibiotics is the main cause of antibiotic resistance. The issue is largely caused by patients' disobedience and medical professionals' over prescriptions. Travelling around the world also makes it easier for resistant strains to proliferate. The problem is made worse by poor hygiene and infection control procedures, which emphasizes the necessity of all-encompassing public health initiatives.

Which entity produces higher antibiotic resistance:

A number of infections, including multidrug-resistant tuberculosis, VRE, and MRSA, are prime examples of the problem caused by antibiotic resistance. Treatment plans are made more difficult by the intricate resistance patterns of these pathogens, which frequently include many antibiotic classes. Clinical judgments and public health initiatives can be influenced by knowledge of the most resistant organisms.

Which Drug Develops a Higher Resistance:

E. coli and Enterococcus usually show resistance to one or more antibiotics, and sometimes to many antibiotic classes, including rifamycin, beta-lactams, macrolides, quinolones, sulphonamides, and tetracyclines, when cefoxitin, ciprofloxacin, or erythromycin inhibit them.

Methods To Get Across Antibiotic Resistance:

By blocking the enzymes that cause resistance, β-lactamase inhibitors can aid in restoring the effectiveness of β-lactamantibiotics.

Proteins that Recognize Peptidoglycan:

These proteins may provide a fresh approach to fighting resistant bacteria by boosting innate immune responses.

Lanthipeptides:

The goal of research on these peptide antibiotics is to create novel therapies for strains that are resistant. Using viruses that infect bacteria to target resistant infections and treat them selectively is known as bacteriophage therapy.

CRISPR Technology Novel Antibiotics:

New antibacterial chemicals and genetic engineering developments bode well for future treatments.

Biofilm Disruption:
Developing methods to stop or disturb biofilms is essential because these structures are infamously hard to cure.

V. Conclusion

Antibiotics are essential for treating infectious infections and their worth and significance cannot be overstated. They should never be viewed as commodities. Antibiotics are essential for the success of sophisticated surgical procedures, such as organ and prosthesis transplants, in addition to being used to treat infectious infections. [20,21]Antibiotics are not perfect, and once the best applications for any newly discovered chemical are determined, it is crucial to limit antibiotic prescriptions to those uses alone. [21,22] This implies that specific "niche" antibiotics ought to be created independently of broad-spectrum medications. With our growing understanding of environmental reservoirs of resistance, it ought to be feasible to anticipate issues in the clinic by anticipating putative resistance mechanisms to either novel or established antibiotics. We must resume a coordinated offensive that fully utilizes the new knowledge and tools that have been made available to us [23,24,25].

References

[1] Davies J, Davies D. Origins And Evolution Of Antibiotic Resistance. Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33.
[2] Alekshun Mn, Levy Sb. Molecular Mechanisms Of Antibacterial Multidrug Resistance. Cell. 2007 Mar 23;128(6):1037-50.
[3] Maxwell A, Dowson Cg, Spencer J. The Molecular Basis Of Antibiotic Action And Resistance. J Mol Biol. 2019 Aug 23;431(18):3367-3369.
[4] Gniadkowski M. Evolution Of Extended-Spectrum Beta-Lactamases By Mutation. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:11-32.
[5] Morar M, Wright Gd. The Genomic Enzymology Of Antibiotic Resistance. Annu Rev Genet. 2010;44:25-51.
[6] Walsh,C., C. Walsheditor, 20043133125, English, Book, Usa, 1-55581-254-6, Washington, Antibiotics: Actions, Origins, Resistance, (X + 335 Pp.), American Society For Microbiology (Asm), Antibiotics: Actions, Origins, Resistance., (2003).
[7] Antimicrobial Resistance Collaborators. (2022). Global Burden Of Bacterial Antimicrobial Resistance In 2019: A Systematic Analysis. The Lancet; 399(10325): P629-655.
[8] Antimicrobial Resistance Information From Fda. Us Food And Drug Administration (Fda). Updated 7/13/2023. Accessed July 19, 2023athttps://Www.Drugs.Com/Article/Antibiotic-Resistance.Html.
[9] Https://Nyulangone.Org/Conditions/Antibiotic-Resistant-Infections/Types.
[10] Long, K. S., J. Poehlsgaard, C. Kehrenberg, S. Schwartz, And B. Vester. 2006. The Cfr Rrna Methyltransferase Confers Resistance To Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, And Streptogramin A Antibiotics. Antimicrobial Agents Chemother. 50:2500-2505.
[11] Gniadkowski, M. 2008. Evolution Of Extended-Spectrum Beta-Lactamases By Mutation. Clin. Microbial. Infect. 14(Suppl. 1):11-32.
[12] D'costa Vm, Mcgrann Km, Hughes Dw, Wright Gd. Sampling The Antibiotic Resistome. Science. 2006 Jan 20;311(5759):374-7.
[13] Menz Bd, Charani E, Gordon Dl, Leather Ajm, Moonesinghe Sr, Phillips Cj. Surgical Antibiotic Prophylaxis In An Era Of Antibiotic Resistance: Common Resistant Bacteria And Wider Considerations For Practice. Infect Drug Resist. 2021 Dec 7; 14:5235-5252.
[14] Gabibov Ag, Dontsova Oa, Egorov Am. Overcoming Antibiotic Resistance In Microorganisms: Molecular Mechanisms. Biochemistry (Mosc). 2020 Nov;85(11):1289-1291.
[15] Osterman, I. A., Dontsova, O. A., And Sergiev, P. V. (2020) Methylation Of Rrna And Antibiotic Resistance, Biochemistry (Moscow), 85, 1335-1349.
[16] Vlasov, V. V., Tikunova, N. V., And Morozov, V. V. (2020) Bacteriophages As Therapeutics: What Hinders Their Application In Medicine, Biochemistry (Moscow), 85, 1350-1361.
[17] Stonik, V. A., Makareva, T. N., And Shubina, L. K. (2020) Antibiotics From Marine Bacteria Biochemistry (Moscow), 85, 1362-1373.
[18] Shemyakin, I. G., Firstova, V. V., Fursova, N. K., Abaev, I. V., Filippovich, S. Yu., Ignatov, S. G., And Dyatlov, I. A. (2020) New Possibilities To Fight Pathogenic Microorganisms, Biochemistry (Moscow), 85, 11374-1388.
[19] Marshall, B. M., D. J. Ochieng, And S. B. Levy. 2009. Commensals: Unappreciated Reservoir Of Antibiotic Resistance. Microbe 4:231-238.
[20] Egorov, A. M., Ulyashova, M. M., And Rubtsova, M. Yu. (2020) Inhibitors Of B-Lactamases. New Life Of B-Lactam Antibiotics, Biochemistry (Moscow), 85, 1292-1309.
[21] Bobrovsky, P. A., Moroz, V. D., Lavrenov, V. N., Manuvera, V. A., And Lazarev, V. N. (2020) Inhibition Of Chlamydial Infection By Crispr/Cas9-Sam Mediated Enhancement Of Human Peptidoglycan Recognition Proteins Gene Expression In Hela Cells, Biochemistry (Moscow), 85, 1310-1318.
[22] Pipiya, S. O., Terekhov, S. S., Mokrushina, Yu. A., Knorre, V. D., Smirnov, I. V., And Gabibov, G. A. (2020) The Use Expanded Chemical Space Of Antibiotics For Creation Artificial Diversity Of Genetically Encoded Antibiotics, Biochemistry (Moscow), 85, 1319-1334.
[23] Baltz, R. H. 2006. Marcel Faber Roundtable: Is Our Antibiotic Pipeline Unproductive Because Of Starvation, Constipation Or Lack Of Inspiration? J. Ind. Microbial. Biotechnology. 33:507-513.
[24] 106. Payne, D. J., M. N. Gwynn, D. J. Holmes, And D. L. Pompliano. 2007. Drugs For Bad Bugs: Confronting The Challenges Of Antibacterial Discovery. Nat. Rev. Drug Discov. 6:29-40.
[25] Projan, S. J. 2003. Why Is Big Pharma Getting Out Of Antibacterial Drug Discovery? Curr. Opin. Microbial. 6:427-430.